Rein Therapeutics
CompanyUnited States
Rein Therapeutics develops one asset, in phase 2 (LTI-03 in idiopathic pulmonary fibrosis). Mostly peptide; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $110M
- 4
- Trials
- 0
- Signals
Pipeline
1Caveolin-1-derived peptide intended to protect alveolar epithelial cells, restore their function, and limit lung fibrosis.
Phase 2, Peptide, idiopathic pulmonary fibrosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials5
- Funding rounds and grants5
- Signals2
- Similar companies6